| Attending joint formulation meetings on pharmaceuticals and special medical materials. | Câncer
> Câncer: a maioria dos tipos | Parceria regulatória
> Trabalhando com órgãos reguladores | 100.000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | Câncer
> Câncer: a maioria dos tipos | Parceria regulatória
> Trabalhando com órgãos reguladores | 5.000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Câncer
> Câncer: a maioria dos tipos | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologia em Saúde (ATS) e reembolso | 5.000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuscular
> Atrofia muscular espinhal (AME) | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologia em Saúde (ATS) e reembolso | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Câncer
> Câncer: a maioria dos tipos | Parceria regulatória
> Participar/facilitar reuniões com formuladores de políticas/reguladores | 5.000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | Câncer
> Câncer: a maioria dos tipos | Parceria regulatória
> Participar/facilitar reuniões com formuladores de políticas/reguladores | 5.000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | Câncer
> Câncer: a maioria dos tipos | Impactando políticas e legislação
> Influenciar políticas e legislações de saúde | 10.000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Câncer
> Câncer: a maioria dos tipos | Impactando políticas e legislação
> Participar de audiências públicas e consultas | 10.000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Saúde geral
> Prestação de serviços de saúde | Defesa de preços e acessibilidade financeira
> Defenda preços justos para medicamentos | 5.000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Câncer
> Câncer: mama | Defesa de preços e acessibilidade financeira
> Defendendo a inclusão do produto em listas de reembolso/formulários nacionais | 10.000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Saúde geral
> Prestação de serviços de saúde | Defesa de preços e acessibilidade financeira
> Defendendo a inclusão do produto em listas de reembolso/formulários nacionais | 5.000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Câncer
> Câncer: neuroendócrino (NET) | Defesa de preços e acessibilidade financeira
> Defendendo a inclusão do produto em listas de reembolso/formulários nacionais | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Câncer
> Câncer: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Defendendo a inclusão do produto em listas de reembolso/formulários nacionais | 10.000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Câncer
> Câncer: mama | Melhorando os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 10.000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Câncer
> Câncer: neuroendócrino (NET) | Melhorando os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuscular
> Atrofia muscular espinhal (AME) | Melhorando os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Câncer
> Câncer: a maioria dos tipos | Melhorando os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 10.000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Câncer
> Câncer: a maioria dos tipos | Contribuição do paciente baseada em evidências
> Use insights do paciente para embasar decisões | 5.000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | Governança institucional
> Garantir representação em órgãos consultivos governamentais | 5.000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Câncer
> Câncer: a maioria dos tipos | Governança institucional
> Trabalhando de forma eficaz em redes com múltiplos stakeholders | 10.000 | National | Sometimes | 119055308347 |
interações
ações & defesa
5 menções
